S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathway Corrigendum in /10.3892/ijo.2023.5494

Wu,Rui; Duan,Liang; Ye,Liwei; Wang,Haiyang; Yang,Xia; Zhang,Yunyuan; Chen,Xian; Zhang,Yan; Weng,Yaguang; Luo,Jingyong; Tang,Min; Shi,Qiong; He,Tongchuan; Zhou,Lan

doi:10.3892/ijo.2013.1796

S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathway

Corrigendum in 10.3892/ijo.2023.5494

Authors:
- Rui Wu
- Liang Duan
- Liwei Ye
- Haiyang Wang
- Xia Yang
- Yunyuan Zhang
- Xian Chen
- Yan Zhang
- Yaguang Weng
- Jingyong Luo
- Min Tang
- Qiong Shi
- Tongchuan He
- Lan Zhou
View Affiliations

Affiliations: Department of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, P.R. China, Molecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA
Published online on: January 23, 2013 https://doi.org/10.3892/ijo.2013.1796
Pages: 1001-1010

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The S100A9 protein, a member of the S100 protein family, is often upregulated in various types of cancer, including hepatocellular carcinoma (HCC). S100A9 acts as a danger signal when secreted to the extracellular space and is thought to play an important role during tumorigenesis. Despite this fact, little is known about the effects of S100A9 in the tumor microenvironment on HCC. Therefore, in this study, we investigated the effects of exogenous S100A9 on the proliferation and invasion of HepG2 HCC cells, as well as the molecular mechanisms underlying these effects. Our results demonstrated that exogenous S100A9 promoted the proliferation, clone formation and invasion of HepG2 cells in vitro, as shown by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltrazolium bromide (MTT), clone formation and transwell invasion assays, respectively, and also promoted tumor growth in vivo by tumorigenicity assays in nude mice. Furthermore, S100A9 increased the phosphorylation of p38 and ERK1/2 mitogen-activated protein kinases (MAPKs) in HepG2 cells. When the phosphorylation of p38 was inhibited by SB203580 (a p38 inhibitor), the S100A9-induced cell invasion was reversed; when the phosphorylation of ERK1/2 was inhibited by PD98059 (an ERK1/2 inhibitor), the S100A9-induced cell proliferation was reversed. These data suggest that the S100A9-induced proliferation and invasion of HepG2 cells are partly mediated by the activation of the MAPK signaling pathway.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Cornella H, Alsinet C and Villanueva A: Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res. 35:821–825. 2011. View Article : Google Scholar
3	Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar
4	Rossi L, Zoratto F, Papa A, et al: Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol. 2:348–359. 2010. View Article : Google Scholar : PubMed/NCBI
5	Donato R: S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 33:637–668. 2001. View Article : Google Scholar : PubMed/NCBI
6	Heizmann CW, Fritz G and Schafer BW: S100 proteins: structure, functions and pathology. Front Biosci. 7:d1356–d1368. 2002. View Article : Google Scholar : PubMed/NCBI
7	Donato R: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 60:540–551. 2003. View Article : Google Scholar : PubMed/NCBI
8	Marenholz I, Heizmann CW and Fritz G: S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun. 322:1111–1122. 2004. View Article : Google Scholar : PubMed/NCBI
9	Benedyk M, Sopalla C, Nacken W, et al: HaCaT keratinocytes overexpressing the S100 proteins S100A8 and S100A9 show increased NADPH oxidase and NF-kappaB activities. J Invest Dermatol. 127:2001–2011. 2007. View Article : Google Scholar
10	Arai K, Yamada T and Nozawa R: Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol. 17:183–188. 2000. View Article : Google Scholar
11	Nemeth J, Stein I, Haag D, et al: S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology. 50:1251–1262. 2009. View Article : Google Scholar
12	Srikrishna G: S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun. 4:31–40. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ghavami S, Chitayat S, Hashemi M, et al: S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol. 625:73–83. 2009. View Article : Google Scholar : PubMed/NCBI
14	Turovskaya O, Foell D, Sinha P, et al: RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 29:2035–2043. 2008. View Article : Google Scholar : PubMed/NCBI
15	Ghavami S, Rashedi I, Dattilo BM, et al: S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol. 83:1484–1492. 2008. View Article : Google Scholar : PubMed/NCBI
16	Hermani A, De Servi B, Medunjanin S, Tessier PA and Mayer D: S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res. 312:184–197. 2006. View Article : Google Scholar : PubMed/NCBI
17	Ghavami S, Kerkhoff C, Chazin WJ, et al: S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim Biophys Acta. 1783:297–311. 2008. View Article : Google Scholar : PubMed/NCBI
18	Ghavami S, Eshragi M, Ande SR, et al: S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res. 20:314–331. 2010. View Article : Google Scholar : PubMed/NCBI
19	Schmidt CM, McKillop IH, Cahill PA and Sitzmann JV: The role of cAMP-MAPK signalling in the regulation of human hepatocellular carcinoma growth in vitro. Eur J Gastroenterol Hepatol. 11:1393–1399. 1999. View Article : Google Scholar : PubMed/NCBI
20	Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC and Tran E: Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 3:192003. View Article : Google Scholar : PubMed/NCBI
21	Nakagawa H and Maeda S: Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int. 2012:1728942012.PubMed/NCBI
22	Ichikawa M, Williams R, Wang L, Vogl T and Srikrishna G: S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res. 9:133–148. 2011. View Article : Google Scholar : PubMed/NCBI
23	You L, Xu LL, Guo YY, et al: Prokaryotic expression, purification and identification of GST-human S100A9 fusion protein. Chin J Biochem Pharm. 32:253–256. 2011.
24	Punathil T, Tollefsbol TO and Katiyar SK: EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase. Biochem Biophys Res Commun. 375:162–167. 2008. View Article : Google Scholar : PubMed/NCBI
25	Ang CW, Nedjadi T, Sheikh AA, et al: Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis. 31:1541–1551. 2010. View Article : Google Scholar
26	Arai K, Takano S, Teratani T, Ito Y, Yamada T and Nozawa R: S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets. 8:243–252. 2008. View Article : Google Scholar : PubMed/NCBI
27	Sakurai T, He G, Matsuzawa A, et al: Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 14:156–165. 2008. View Article : Google Scholar
28	Spaziani A, Alisi A, Sanna D and Balsano C: Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1. J Biol Chem. 281:10983–10989. 2006. View Article : Google Scholar
29	Gailhouste L, Ezan F, Bessard A, et al: RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo. Int J Cancer. 126:1367–1377. 2010.PubMed/NCBI
30	Guo L, Guo Y, Xiao S and Shi X: Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci. 77:1869–1878. 2005. View Article : Google Scholar : PubMed/NCBI
31	Min L, He B and Hui L: Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol. 21:10–20. 2011. View Article : Google Scholar : PubMed/NCBI
32	Simard JC, Girard D and Tessier PA: Induction of neutrophil degranulation by S100A9 via a MAPK-dependent mechanism. J Leukoc Biol. 87:905–914. 2010. View Article : Google Scholar : PubMed/NCBI
33	Sunahori K, Yamamura M, Yamana J, et al: The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther. 8:R692006. View Article : Google Scholar
34	Ehlermann P, Eggers K, Bierhaus A, et al: Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol. 5:62006. View Article : Google Scholar
35	Hiwatashi K, Ueno S, Abeyama K, et al: A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol. 15:923–933. 2008. View Article : Google Scholar : PubMed/NCBI
36	Hoefen RJ and Berk BC: The role of MAP kinases in endothelial activation. Vascul Pharmacol. 38:271–273. 2002. View Article : Google Scholar : PubMed/NCBI
37	Lee HC, Tian B, Sedivy JM, Wands JR and Kim M: Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology. 131:1208–1217. 2006. View Article : Google Scholar : PubMed/NCBI
38	Montesano R, Soriano JV, Hosseini G, Pepper MS and Schramek H: Constitutively active mitogen-activated protein kinase kinase MEK1 disrupts morphogenesis and induces an invasive phenotype in Madin-Darby canine kidney epithelial cells. Cell Growth Differ. 10:317–332. 1999.
39	Behren A, Binder K, Vucelic G, et al: The p38 SAPK pathway is required for Ha-ras induced in vitro invasion of NIH3T3 cells. Exp Cell Res. 303:321–330. 2005. View Article : Google Scholar : PubMed/NCBI
40	Huang X, Chen S, Xu L, et al: Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 65:3470–3478. 2005.
41	Ringshausen I, Dechow T, Schneller F, et al: Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia. 18:1964–1970. 2004. View Article : Google Scholar : PubMed/NCBI